Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorFernández de Retana, Sofía
dc.contributor.authorMarazuela Fuentes, Paula
dc.contributor.authorSolé Piñol, Montserrat
dc.contributor.authorColell Dinares, Guillem
dc.contributor.authorBonaterra Pastra, Anna
dc.contributor.authorSánchez-Quesada, Jose Luis
dc.contributor.authorMontaner Villalonga, Joan
dc.contributor.authorHernandez Guillamon, Maria Mar
dc.date.accessioned2019-07-05T07:02:39Z
dc.date.available2019-07-05T07:02:39Z
dc.date.issued2019-05-10
dc.identifier.citationFernández de Retana S, Marazuela P, Solé M, Colell G, Bonaterra A, Sánchez-Quesada JL, et al. Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice. Alzheimers Res Ther. 2019;11(1):42.
dc.identifier.issn1758-9193
dc.identifier.urihttps://hdl.handle.net/11351/4181
dc.descriptionAPP23; Malaltia d'Alzheimer; ApoJ
dc.description.sponsorshipFunded by Instituto de Salud Carlos III (ISCIII) [PI17/00275, PI14/01134, and PI13/00364], co-financed by the European Regional Development Fund (FEDER), and Fundació La Marató de TV3 [40/U/2014]. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S-Q is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H-G is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. ICN2 acknowledges the support of the Spanish MINECO through the Severo Ochoa Centers of Excellence Programme, under Grant SEV-2013-0295.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesAlzheimer's Research and Therapy;11(1)
dc.rightsAttribution-ShareAlike 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-sa/4.0/
dc.sourceScientia
dc.subjectAlzheimer, Malaltia d' - Tractament
dc.subjectGlicoproteïnes
dc.subjectRatolins transgènics
dc.subject.meshAlzheimer Disease
dc.subject.mesh/drug therapy
dc.subject.meshClusterin
dc.subject.meshMice, Transgenic
dc.titlePeripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s13195-019-0498-8
dc.subject.decsenfermedad de Alzheimer
dc.subject.decs/tratamiento farmacológico
dc.subject.decsclusterina
dc.subject.decsratones transgénicos
dc.relation.publishversionhttps://alzres.biomedcentral.com/articles/10.1186/s13195-019-0498-8
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Fernández de Retana S, Marazuela P, Solé M, Colell G, Bonaterra A, Montaner J, Hernández-Guillamon M] Laboratori de Recerca Neurovascular, Vall d’Hebron Institut de Recerca, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Sánchez-Quesada JL] Grup de Bioquímica Cardiovascular, Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona , Spain.
dc.identifier.pmid31077261
dc.identifier.wosWOS:000467681600002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple